Autres langues CSPC Pharmaceutical Group Limited

Actions

1093

HK1093012172

Produits pharmaceutiques

Marché Fermé - Hong Kong S.E. 10:08:36 21/09/2026			Varia. 5j.	Varia. 1 janv.
9,605 ^HKD	+7,56 %		+10,28 %	+13,94 %

15:53	Le secteur pharmaceutique mise sur l'IA pour réduire ses coûts et ses délais	RE
10:51	Les États-Unis envisagent des règles autorisant l'investissement américain dans les médicaments chinois	MT

Autres langues

15:53	Pharma sector doubles down on AI to slash costs, timelines
10:51	US Considers Rules Allowing American Investment in Chinese Drugs
16/09	CSPC Pharmaceutical Group Limited Initiates Phase II Clinical Trial Of SYH2069 Injection For Treatment Of Type 2 Diabetes Mellitus In Adult Patients At First Centre In China
16/09	Pharma sector doubles down on AI to slash costs, timelines
16/09	CSPC Pharma Begins Diabetes Drug Trial in China
15/09	CSPC Pharmaceutical Gets Breakthrough Therapy Designation for Lung Cancer Drug
15/09	CSPC Pharmaceutical says SYS6010 granted breakthrough therapy designation by NMPA
15/09	CSPC Pharmaceutical Group Limited Receives Breakthrough Therapy Designation For SYS6010 By NMPA In China For Treatment Of Actionable Genomic Alteration-Negative Non-Squamous Non-Small Cell Lung Cancer
14/09	CSPC Pharmaceutical Group Limited Presents Phase I/II Clinical Trial Data Of SYS6010 In Combination With Enlonstobart For Treatment Of Advanced NSCLC At 2026 World Conference On Lung Cancer
09/09	CSPC Pharma's SYH9087 Injection Gets China Nod for Parkinson's Disease Trial
09/09	CSPC Pharma Gets Clinical Trial Nod in China for Solid Tumors Drug
09/09	CSPC Pharmaceutical Group Limited Announces Dopamine Receptor Agonist Rotigotine Long-Acting Injection (SYH9087 Injection)
09/09	CSPC Pharmaceutical Group Limited Obtains Clinical Trial Approval In China For Goserelin Sustained-Release Injection (SYH9102 Injection)
08/09	CSPC Pharmaceutical Group Limited SYH2083 Eye Drops Obtain Clinical Trial Approval In China
08/09	CSPC Pharmaceutical Gets China Approval for Eye Drug Clinical Trials
07/09	CSPC Pharmaceutical Group Limited Initiates Phase II Clinical Trial of SYH2085 Tablets for Treatment of Uncomplicated Influenza in Adults in China
07/09	CSPC Pharma Begins Phase II Study of Influenza Drug in China
01/09	CSPC Pharma's Cancer Drug Gets Breakthrough Therapy Designation for New Indication in China
01/09	CSPC Pharma's SYS6010 Gets Breakthrough Therapy Designation for New Indication in China
01/09	CSPC Pharma Initiates Depression Drug Candidate Trial in China
01/09	CSPC Pharmaceutical Group Limited Initiates Phase I Clinical Trial Of SYH2056 Tablets For The Treatment Of Depression In China
01/09	CSPC Pharmaceutical Group Limited Receives Breakthrough Therapy Designation For SYS6010 For Treatment Of Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma
31/08	CSPC Pharma Begins Trial for Weight Management Drug in China
31/08	Cspc Pharmaceutical Group Limited Initiates Phase I Clinical Trial of Syh2092 Injection for Weight Management in Adult Patients with Overweight or Obesity At the First Centre in China
28/08	Cspc Pharmaceutical Group Limited Initiates Phase Ii Clinical Trial of Syh2069 Injection for Weight Management in Adult Patients with Overweight or Obesity At the First Centre in China